Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for JCR Pharmaceuticals Co., Ltd. (4552:JPX), powered by AI.
JCR Pharmaceuticals Co., Ltd. is currently trading at ¥466. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for JCR Pharmaceuticals Co., Ltd. on Alpha Lenz.
JCR Pharmaceuticals Co., Ltd.'s P/E ratio is -12.1.
“JCR Pharmaceuticals Co., Ltd. trades at a P/E of -12.1 (undervalued) with modest ROE of -9.2%.”
Ask for details →JCR Pharmaceuticals Co., Ltd. is a prominent biotechnology company engaged in the development, manufacture, and distribution of pharmaceutical products. The company focuses primarily on innovative treatments for rare diseases and biopharmaceuticals, utilizing advanced recombinant DNA and protein engineering technologies. JCR Pharmaceuticals is recognized for its contributions to enzyme replacement therapies and regenerative medicines, which address unmet medical needs in diverse therapeutic areas such as lysosomal storage disorders. Incorporated in Japan, JCR Pharmaceuticals plays a significant role in the pharmaceutical industry by investing heavily in research and development to bring cutting-edge therapies to the global market. The company's dedication to innovation has established it as a key player in the biopharmaceutical segment, where it actively collaborates with academic institutions and industry partners to enhance its product pipeline. With its strong emphasis on improving patient outcomes through advanced biologics, JCR Pharmaceuticals continues to bolster its market position, impacting sectors such as healthcare and life sciences with its specialized offerings.
“JCR Pharmaceuticals Co., Ltd. trades at a P/E of -12.1 (undervalued) with modest ROE of -9.2%.”
Ask for details →JCR Pharmaceuticals Co., Ltd. (ticker: 4552) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 987 employees. Market cap is $57.7B.
The current price is 466 with a P/E ratio of -12.13x and P/B of 1.23x.
ROE is -9.22% and operating margin is -20.11%. Annual revenue is $33.1B.